| 0 (0%) | 12-27 04:19 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 39.66  |
1-year : | 46.32 |
| Resists | First : | 33.95 |
Second : | 39.66 |
| Pivot price | 32.11 |
|||
| Supports | First : | 31.5 |
Second : | 29.97 |
| MAs | MA(5) : | 33.24 |
MA(20) : | 32.04 |
| MA(100) : | 29.14 |
MA(250) : | 0 | |
| MACD | MACD : | 0.6 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 92.2 |
D(3) : | 94 |
| RSI | RSI(14): 63.8 |
|||
| 52-week | High : | 33.95 | Low : | 17.23 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GMAB ] has closed below upper band by 13.8%. Bollinger Bands are 9.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 33.99 - 34.16 | 34.16 - 34.27 |
| Low: | 32.9 - 33.13 | 33.13 - 33.27 |
| Close: | 33.09 - 33.44 | 33.44 - 33.66 |
Sat, 27 Dec 2025
Block Trades: How GMAB stock performs in rate cut cycles - July 2025 Short Interest & High Yield Equity Trading Tips - moha.gov.vn
Fri, 26 Dec 2025
This Cancer-Fighting Biotech Surges Into Buy Zone As Earnings Soar 131% - Investor's Business Daily
Tue, 23 Dec 2025
Genmab A/S (NASDAQ:GMAB) Reaches New 1-Year High - Still a Buy? - MarketBeat
Sat, 13 Dec 2025
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Evolent Health (EVH) and AbSci (ABSI) - The Globe and Mail
Mon, 08 Dec 2025
How Genmab’s US$2.5 Billion Merus Deal Financing Could Impact Genmab (CPSE:GMAB) Investors - Yahoo Finance
Sun, 07 Dec 2025
Genmab A/S Sponsored ADR $GMAB Shares Sold by American Century Companies Inc. - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 616 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 10.2 (%) |
| Shares Short | 11,900 (K) |
| Shares Short P.Month | 10,540 (K) |
| EPS | 2.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 93.41 |
| Profit Margin | 41.1 % |
| Operating Margin | 44.9 % |
| Return on Assets (ttm) | 13.3 % |
| Return on Equity (ttm) | 29.4 % |
| Qtrly Rev. Growth | 17.3 % |
| Gross Profit (p.s.) | 5.89 |
| Sales Per Share | 6.25 |
| EBITDA (p.s.) | 2.38 |
| Qtrly Earnings Growth | 107.5 % |
| Operating Cash Flow | 1,370 (M) |
| Levered Free Cash Flow | 956 (M) |
| PE Ratio | 14.59 |
| PEG Ratio | 0 |
| Price to Book value | 0.35 |
| Price to Sales | 5.34 |
| Price to Cash Flow | 15.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|